AbbVie | ABBV - Sales Revenues



AbbVie reported $15.42B in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Abbott USD 11.42B 1.06B Jun/2025
ALKERMES USD 390.7M 84.2M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Biogen USD 2.6B 170M Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Eisai JPY 202.65B 14.41B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
J&J USD 23.74B 1.85B Jun/2025
Medtronic USD 8.6B 330M Jun/2025
Merck USD 15.81B 280M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Pacira USD 181.1M 12.18M Jun/2025
Perrigo USD 1.06B 20M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 9.99B 90M Jun/2025
UCB EUR 3.49B 129M Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
United Therapeutics USD 798.6M 4.2M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025
Zoetis USD 2.46B 240M Jun/2025